Regeneron CEO: Manufacturing Not Up to Snuff for COVID-19 Vaccines, Therapies

Source: FiercePharma

Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development. But success in the clinic means nothing if drugmakers can’t produce a therapy or vaccine fast enough—and the company’s helmsman is sounding the alarm, according to a FiercePharma report.

While U.S. distribution channels for possible COVID-19 vaccines and therapies are adequate to meet patients’ needs, manufacturing capacity to fulfill those orders is “limited,” Regeneron CEO Len Schleifer told CNN’s “State of the Union” Sunday. 

Read the full article.

Related Content